Relmada terminates esmethadone license agreement with Inturrisi and Manfredi

RELMADA THERAPEUTICS, INC.

On July 7, 2025, Relmada delivered termination notice for the esmethadone License Agreement with Drs. Inturrisi and Manfredi.
The agreement granted exclusive worldwide license for esmethadone in psychiatric use; obligations cease 90 days after notice.
Relmada had been paying $45,000 quarterly under the agreement; upfront fee of $180,000 paid in 2018.
The termination ends Relmada's participation in the previously announced esmethadone development program.
No commercial sales, royalties, or sublicense payments had occurred under the agreement.

item 1.02

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.